Hercules Capital, Inc. (HTGC)
Hercules Capital, Inc. (HTGC) is a specialty finance company that provides debt and equity financing to technology, life sciences, and broader venture growth companies. Founded in 2003, the firm primarily focuses on early and growth-stage companies, offering customized capital solutions to support their development and expansion efforts. Hercules Capital is known for its sector expertise and attention to innovation-driven markets.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| August 19, 2025 | $0.40 | 2025-08-12 | 2025-08-12 |
| August 19, 2025 | $0.07 | 2025-08-12 | 2025-08-12 |
| May 20, 2025 | $0.07 | 2025-05-13 | 2025-05-13 |
| May 20, 2025 | $0.40 | 2025-05-13 | 2025-05-13 |
| March 5, 2025 | $0.40 | 2025-02-26 | 2025-02-26 |
Dividends Summary
- Hercules Capital, Inc. has issued 106 dividend payments over the past 20 years
- The most recent dividend was paid 32 days ago, on August 19, 2025
- The highest dividend payed out to investors during this period was $0.4 per share
- The average dividend paid during this period was $0.25 per share.
Company News
Ashland Inc. announced Karl Bostaph's retirement as senior vice president of operations, with Wayne Muil taking over the role effective immediately. Muil brings over 25 years of global operations experience and will oversee Ashland's production facilities worldwide.
The article recommends investing in three business development companies (BDCs) - Ares Capital, PennantPark Floating Rate Capital, and Hercules Capital - to generate $500 in annual dividend income by 2025 with an initial investment of $5,040. The BDCs offer high dividend yields ranging from 8.7% to 11.3%.
Hercules Capital Inc.'s Q2 2024 net investment income matched estimates, but declined year-over-year due to higher operating expenses. The company's total investment income and portfolio value remained strong, but expenses rose due to increased interest and compensation costs.
Eloxx Pharmaceuticals, a biopharmaceutical company, has secured an additional $3.175 million in funding through a loan agreement amendment with Hercules Capital and other lenders. The funding will be used for the company's operations and development of its ELX-02 compound.
Related Companies
